Active ingredientZileutonCat. No. P-Z016-001CAS 111406-87-2Family · Pharmaceutical analytical standards
Zileuton
An oral medicine for the prevention and long-term treatment of asthma, introduced in 1996: it inhibits 5-lipoxygenase, the enzyme that makes leukotrienes, instead of blocking their receptors like montelukast and zafirlukast. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.
Did you know?In mice it has also been studied against chronic myeloid leukaemia, alone or together with imatinib, and in an experimental model of dementia.
Go to the active ingredient →Active ingredientZileutonCat. No. P-Z016-001CAS 111406-87-2
Pharmacopoeial impurityZileuton USP Related Compound ACat. No. P-Z016-002CAS 171370-49-3
Pharmacopoeial impurityZileuton USP Related Compound BCat. No. P-Z016-003CAS 97978-07-9
Pharmacopoeial impurityZileuton USP Related Compound CCat. No. P-Z016-004CAS 22720-75-8
MetaboliteZileuton Glucuronide (Mixture of Diastereomers)Cat. No. P-Z016-005
Isotopically labelledZileuton-d4Cat. No. P-Z016-006CAS 1189878-76-9![1-(benzo[b]thiophen-2-yl)ethanol](https://img.vitasanlabs.com/vsl-struct/P-Z016-007.svg?v=41e934f030)
Impurity1-(benzo[b]thiophen-2-yl)ethanolCat. No. P-Z016-007CAS 51868-95-2
ImpurityN-Des(aminocarbonyl) ZileutonCat. No. P-Z016-008CAS 118564-89-9
ImpurityZileuton Impurity 1Cat. No. P-Z016-009CAS 1026256-93-8
ImpurityZileuton Impurity 2Cat. No. P-Z016-010
ImpurityZileuton SulfoxideCat. No. P-Z016-011CAS 1147524-83-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.